Molecular Partners Earnings Estimate
| MOLN Stock | USD 3.60 0.05 1.37% |
Molecular | Build AI portfolio with Molecular Stock |
Molecular Partners Earnings Estimation Breakdown
The calculation of Molecular Partners' earning per share is based on the data from the past 12 consecutive months, used for reporting the company's financial figures. The next projected EPS of Molecular Partners is estimated to be -0.4425 with the future projection ranging from a low of -0.4425 to a high of -0.4425. Please be aware that this consensus of annual earnings estimates for Molecular Partners AG is based on EPS before non-recurring items and includes expenses related to employee stock options.Last Reported EPS
-0.44 Lowest | Expected EPS | -0.44 Highest |
Molecular Partners Earnings Projection Consensus
Suppose the current estimates of Molecular Partners' value are higher than the current market price of the Molecular Partners stock. In this case, investors may conclude that Molecular Partners is overpriced and will exhibit bullish sentiment. On the other hand, if the present value is lower than the stock price, analysts may conclude that the market undervalues the equity. These scenarios may suggest that the market is not as efficient as it should be at the estimation time, and Molecular Partners' stock will quickly adjusts to the new information provided by the consensus estimate.
| Number of Analysts | Historical Accuracy | Last Reported EPS | Estimated EPS for 31st of December 2025 | Current EPS (TTM) | |
| 4 | 47.92% | 0.0 | -0.4425 | -2.12 |
Molecular Partners Earnings per Share Projection vs Actual
Actual Earning per Share of Molecular Partners refers to what the company shows during its earnings calls or quarterly reports. The Expected EPS is what analysts covering Molecular Partners AG predict the company's earnings will be in the future. The higher the earnings per share of Molecular Partners, the better is its profitability. While calculating the Earning per Share, we use the weighted ratio, as the number of shares outstanding can change over time.Molecular Partners Estimated Months Earnings per Share
For an investor who is primarily interested in generating an income out of investing in entities such as Molecular Partners, the EPS ratio can tell if the company is intending to increase its current dividend. Although EPS is an essential tool for investors, it should not be used in isolation. EPS of Molecular Partners should always be considered in relation to other companies to make a more educated investment decision.Molecular Quarterly Analyst Estimates and Surprise Metrics
Earnings surprises can significantly impact Molecular Partners' stock price both in the short term and over time. Negative earnings surprises usually result in a price decline. However, it has been seen that positive earnings surprises lead to an immediate rise in a stock's price and a gradual increase over time. This is why we often hear news about some companies beating earning projections. Financial analysts spend a large amount of time predicting earnings per share (EPS) along with other important future indicators. Many analysts use forecasting models, management guidance, and additional fundamental information to derive an EPS estimate.
| Reported | Fiscal Date | Estimated EPS | Reported EPS | Surprise | |||
|---|---|---|---|---|---|---|---|
null | null | null | null | null | 0 | ||
null | null | null | null | null | 0 | ||
2025-04-17 | 2025-03-31 | -0.37 | -0.45 | -0.08 | 21 | ||
2025-03-06 | 2024-12-31 | -0.39 | -0.3 | 0.09 | 23 | ||
2024-10-31 | 2024-09-30 | -0.6288 | -0.5629 | 0.0659 | 10 | ||
2024-08-27 | 2024-06-30 | -1.26 | -0.46 | 0.8 | 63 | ||
2024-05-16 | 2024-03-31 | -1 | -0.6 | 0.4 | 40 | ||
2024-03-14 | 2023-12-31 | -0.97 | -0.6 | 0.37 | 38 | ||
2023-10-26 | 2023-09-30 | 0 | -0.3943 | -0.3943 | 0 | ||
2023-08-28 | 2023-06-30 | -0.87 | -0.5417 | 0.3283 | 37 | ||
2023-05-11 | 2023-03-31 | 0 | -0.4906 | -0.4906 | 0 | ||
2023-03-09 | 2022-12-31 | -0.9 | -0.54 | 0.36 | 40 | ||
2022-10-27 | 2022-09-30 | -0.6559 | -0.4238 | 0.2321 | 35 | ||
2022-08-29 | 2022-06-30 | -0.6559 | 4.59 | 5.2459 | 799 | ||
2022-05-12 | 2022-03-31 | -0.6559 | 4.62 | 5.2759 | 804 | ||
2022-03-15 | 2021-12-31 | -1.04 | -0.56 | 0.48 | 46 | ||
2021-10-28 | 2021-09-30 | -0.6013 | -0.6013 | 0.0 | 0 | ||
2021-08-26 | 2021-06-30 | -0.6231 | -0.6231 | 0.0 | 0 | ||
2021-06-16 | 2021-03-31 | -0.7915 | -0.6177 | 0.1738 | 21 | ||
2021-02-26 | 2020-12-31 | 0 | -0.6009 | -0.6009 | 0 | ||
2020-12-31 | 2020-09-30 | 0 | -0.7589 | -0.7589 | 0 | ||
2020-09-30 | 2020-06-30 | 0 | -0.6524 | -0.6524 | 0 | ||
2020-06-30 | 2020-03-31 | 0 | -0.5528 | -0.5528 | 0 | ||
2020-03-31 | 2019-12-31 | 0 | -0.6406 | -0.6406 | 0 | ||
2019-12-31 | 2019-09-30 | 0 | -0.5658 | -0.5658 | 0 | ||
2019-09-30 | 2019-06-30 | 0 | -0.5485 | -0.5485 | 0 | ||
2019-06-30 | 2019-03-31 | 0 | -0.3061 | -0.3061 | 0 | ||
2019-03-31 | 2018-12-31 | 0 | -0.3001 | -0.3001 | 0 | ||
2018-12-31 | 2018-09-30 | 0 | -0.6068 | -0.6068 | 0 | ||
2018-09-30 | 2018-06-30 | 0 | -0.6077 | -0.6077 | 0 | ||
2018-06-30 | 2018-03-31 | 0 | -0.2832 | -0.2832 | 0 | ||
2018-03-31 | 2017-12-31 | 0 | -0.2909 | -0.2909 | 0 | ||
2017-12-31 | 2017-09-30 | 0 | -0.1482 | -0.1482 | 0 | ||
2017-09-30 | 2017-06-30 | 0 | -0.1491 | -0.1491 | 0 | ||
2017-06-30 | 2017-03-31 | 0 | -0.5851 | -0.5851 | 0 | ||
2017-03-31 | 2016-12-31 | 0 | -0.3695 | -0.3695 | 0 | ||
2016-12-31 | 2016-09-30 | 0 | -0.1792 | -0.1792 | 0 | ||
2016-09-30 | 2016-06-30 | 0 | -0.2574 | -0.2574 | 0 | ||
2016-06-30 | 2016-03-31 | 0 | -0.2796 | -0.2796 | 0 | ||
2016-03-31 | 2015-12-31 | 0 | -0.2191 | -0.2191 | 0 | ||
2015-12-31 | 2015-09-30 | 0 | 0.0595 | 0.0595 | 0 | ||
2015-09-30 | 2015-06-30 | 0 | 0.256 | 0.256 | 0 | ||
2015-06-30 | 2015-03-31 | 0 | -0.2416 | -0.2416 | 0 | ||
2015-03-31 | 2014-12-31 | 0 | -0.134 | -0.134 | 0 | ||
2014-12-31 | 2014-09-30 | 0 | -0.2799 | -0.2799 | 0 | ||
2014-09-30 | 2014-06-30 | 0 | 0.069 | 0.069 | 0 | ||
2014-06-30 | 2014-03-31 | 0 | 0.0513 | 0.0513 | 0 | ||
2014-03-31 | 2013-12-31 | 0 | 0.0515 | 0.0515 | 0 |
About Molecular Partners Earnings Estimate
The earnings estimate module is a useful tool to check what professional financial analysts are assuming about the future of Molecular Partners earnings. We show available consensus EPS estimates for the upcoming years and quarters. Investors can also examine how these consensus opinions have evolved historically. We show current Molecular Partners estimates, future projections, as well as estimates 1, 2, and three years ago. Investors can search for a specific entity to conduct investment planning and build diversified portfolios. Please note, earnings estimates provided by Macroaxis are the average expectations of expert analysts that we track. If a given stock such as Molecular Partners fails to match professional earnings estimates, it usually performs purely. Wall Street refers to that as a 'negative surprise.' If a company 'beats' future estimates, it's usually called an 'upside surprise.'
Please read more on our stock advisor page.| Last Reported | Projected for Next Year | ||
| Retained Earnings | -246.3 M | -234 M | |
| Earnings Yield | (0.39) | (0.37) | |
| Price Earnings Ratio | (2.56) | (2.68) | |
| Price Earnings To Growth Ratio | 0.16 | 0.15 |
Pair Trading with Molecular Partners
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Molecular Partners position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Molecular Partners will appreciate offsetting losses from the drop in the long position's value.Moving against Molecular Stock
| 0.67 | WF | Woori Financial Group Earnings Call This Week | PairCorr |
| 0.66 | CGEN | Compugen | PairCorr |
| 0.65 | SHG | Shinhan Financial Earnings Call This Week | PairCorr |
| 0.59 | KB | KB Financial Group Earnings Call Tomorrow | PairCorr |
| 0.56 | PFE | Pfizer Inc | PairCorr |
The ability to find closely correlated positions to Molecular Partners could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Molecular Partners when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Molecular Partners - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Molecular Partners AG to buy it.
The correlation of Molecular Partners is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Molecular Partners moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Molecular Partners moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Molecular Partners can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Molecular Partners AG. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in bureau of economic analysis. You can also try the Portfolio Rebalancing module to analyze risk-adjusted returns against different time horizons to find asset-allocation targets.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Molecular Partners. If investors know Molecular will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Molecular Partners listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (2.12) | Revenue Per Share | Quarterly Revenue Growth (1.00) | Return On Assets | Return On Equity |
The market value of Molecular Partners is measured differently than its book value, which is the value of Molecular that is recorded on the company's balance sheet. Investors also form their own opinion of Molecular Partners' value that differs from its market value or its book value, called intrinsic value, which is Molecular Partners' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Molecular Partners' market value can be influenced by many factors that don't directly affect Molecular Partners' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Molecular Partners' value and its price as these two are different measures arrived at by different means. Investors typically determine if Molecular Partners is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Molecular Partners' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.